Why Kura Oncology Inc (KURA) Stock Is Rising
As of 2026-08-25, Kura Oncology Inc (KURA) has a next-year EPS growth estimate of 26.30%. Featured in 2 EPS revision reports, most recently on 2026-08-19.
Why KURA Stock Is Rising
- +EPS Estimate Upgraded: Analysts raised Kura Oncology Inc's next-year EPS growth estimate from 25.64% to 25.78% on 2026-08-21.
- →Estimate Trending Higher: Since detection, the estimate has moved up a net +0.52 pp to 26.30% across 1 upward revision.
- ·Current-Year Growth: Projected at -1.28%, supporting the forward estimate revision.
News Context
The primary driver is the upward revision to KURA's next-year EPS growth estimate, which rose from 25.64% to 25.78% on 2026-08-21 and now stands at 26.30%. This upgrade likely reflects the company's Q2 2026 earnings release, along with encouraging long-term ziftomenib combination data in AML and darlifarnib presentations in renal cell carcinoma. The continued climb from 25.78% to 26.30% indicates strengthening analyst sentiment beyond the initial revision.
Generated 2026-08-25 · news as of 2026-08-25
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 26.30%
- EPS growth this year
- -1.28%
- EPS next quarter (est)
- -$0.82
- Last price
- $13.59
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-08-25 | 26.30% | -1.28% | -$0.82 | $13.59 |
| 2026-08-24 | 26.30% | -1.28% | -$0.82 | $12.40 |
| 2026-08-23 | 25.78% | -2.00% | -$0.82 | $11.89 |
| 2026-08-21 | 25.78% | -2.00% | -$0.82 | $11.89 |
| 2026-08-20 | 25.64% | -2.45% | -$0.83 | $11.71 |
| 2026-08-19 | 25.64% | -2.45% | -$0.83 | $12.53 |
| 2026-08-18 | 25.64% | -2.45% | -$0.83 | $12.33 |
| 2026-08-17 | 25.64% | -2.45% | -$0.83 | $11.28 |
| 2026-08-16 | 25.64% | -2.45% | -$0.83 | $10.86 |
| 2026-08-14 | 25.64% | -2.45% | -$0.83 | $10.86 |
| 2026-08-13 | 25.64% | -2.45% | -$0.83 | $10.09 |
| 2026-08-12 | 25.18% | -9.71% | -$0.88 | $9.94 |
| 2026-08-11 | 25.18% | -9.71% | -$0.88 | $9.93 |
| 2026-08-10 | 25.18% | -9.71% | -$0.88 | $9.85 |
| 2026-08-09 | 25.18% | -9.71% | -$0.88 | $9.57 |
| 2026-08-07 | 25.18% | -9.71% | -$0.88 | $9.57 |
| 2026-08-06 | 25.18% | -9.71% | -$0.88 | $9.28 |
| 2026-08-05 | 25.18% | -9.71% | -$0.88 | $9.20 |
| 2026-08-04 | 25.18% | -9.71% | -$0.88 | $9.47 |
| 2026-08-03 | 25.18% | -9.71% | -$0.88 | $9.19 |
| 2026-08-02 | 25.18% | -9.71% | -$0.88 | $9.01 |
| 2026-07-31 | 25.18% | -9.71% | -$0.88 | $9.01 |
| 2026-07-30 | 25.18% | -9.71% | -$0.88 | $9.31 |
| 2026-07-29 | 25.18% | -9.71% | -$0.88 | $8.93 |
| 2026-07-28 | 25.18% | -9.71% | -$0.88 | $9.31 |
| 2026-07-27 | 25.18% | -9.71% | -$0.88 | $10.15 |
| 2026-07-26 | 25.18% | -9.71% | -$0.88 | $10.39 |
| 2026-07-24 | 25.18% | -9.71% | -$0.88 | $10.39 |
| 2026-07-23 | 25.18% | -9.71% | -$0.88 | $10.45 |
| 2026-07-22 | 25.18% | -9.71% | -$0.88 | $10.54 |
Reports Featuring KURA
Recent News
- Kura Oncology, Inc. Q2 2026 Earnings Call SummaryMoby
- Kura Oncology: Q2 Earnings SnapshotAssociated Press
- Kura Oncology Reports Second Quarter 2026 Financial ResultsGlobeNewswire
- Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib's Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026GlobeNewswire
- Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AMLGlobeNewswire
- Kura Oncology Highlights Darlifarnib's Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development StrategyGlobeNewswire
Screen Performance
Aggregate stats across all 2014 tickers our top-EPS-revision screen has flagged over the past 146 days.
- Median return since detection
- +3.1%
- % of tickers in the green
- 56%
- Median return on winners
- +19.9%
- Large revisions captured
- 1606
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
Why did Kura Oncology Inc (KURA) stock go up recently?▾
Kura Oncology Inc (KURA) stock has risen following an analyst upgrade of its next-year EPS growth estimate from 25.64% to 25.78% on 2026-08-21. Since detection, the estimate has moved up a net +0.52 pp to 26.30%. EPS estimate upgrades are among the strongest leading indicators of stock outperformance.
What is Kura Oncology Inc's next-year EPS growth estimate?▾
As of 2026-08-25, Kura Oncology Inc (KURA) has a next-year EPS growth estimate of 26.30%, based on analyst consensus.
When was the latest EPS estimate revision for KURA?▾
The most recent revision occurred on 2026-08-24, when analysts adjusted the next-year EPS growth estimate from 25.78% to 26.30%.
What sector and industry does Kura Oncology Inc belong to?▾
Kura Oncology Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. KURA appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Kura Oncology Inc (KURA) appears here because it was detected by our daily top-EPS-revision-performer screen.